Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04567303
Other study ID # BP41670
Secondary ID
Status Recruiting
Phase Phase 1
First received
Last updated
Start date October 28, 2020
Est. completion date December 29, 2027

Study information

Verified date June 2024
Source Hoffmann-La Roche
Contact BP41670 https://forpatients.roche.com/
Phone 888-662-6728 (U.S. Only)
Email global-roche-genentech-trials@gene.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a first in-human study to investigate the safety, tolerability and efficacy of zifibancimig administered through intravitreal (IVT) injections and via the Port Delivery (PD) implant in participants with neovascular age-related macular degeneration (nAMD)


Recruitment information / eligibility

Status Recruiting
Enrollment 251
Est. completion date December 29, 2027
Est. primary completion date February 9, 2026
Accepts healthy volunteers No
Gender All
Age group 50 Years and older
Eligibility Part 1, Part 2 and Part 3 Inclusion Criteria: - Willing to allow AH collection. Part 1 and Part 2 Ocular Inclusion Criteria for Study Eye: - Choroidal neovascularization (CNV) exclusively due to age-related macular degeneration (AMD). - Anti-vascular endothelial growth factor (VEGF) or anti-VEGF/Angiopoietin-2 (Ang-2) IVT treatment-naïve, or pre-treated with anti-VEGF or anti-VEGF/Ang-2 no less than two months prior to Day 1. - Sufficiently clear ocular media and adequate pupillary dilatation to allow for analysis and grading by the central reading center of fundus photography (FP), fluorescein angiography (FA), fundus autofluorescence (FAF), and spectral domain optical coherence tomography (SD-OCT) images. - Decreased BCVA attributable primarily to nAMD, with BCVA letter score of 78 to 34 letters (inclusive) on ETDRS-like charts at screening. In case both eyes of a participant are eligible, the eye with the lower BCVA score should become the study eye. Part 3 Ocular Inclusion Criteria for Study Eye: - CNV exclusively due to AMD. - Diagnosis of nAMD within nine months prior to the screening visit. - Previous treatment with at least two IVT anti-VEGF or anti-VEGF/Ang-2 administrations IVT for nAMD. The last IVT administration must have occurred at least 21 days prior to the screening visit. - Demonstrated response to prior IVT anti-VEGF or anti-VEGF/Ang-2 treatment since diagnosis. - Availability of historical VA data prior to the first anti-VEGF or anti-VEGF/Ang-2 treatment for nAMD. - Sufficiently clear ocular media and adequate pupillary dilatation to allow for analysis and grading. - Decreased BCVA attributable primarily to nAMD with letter score of 78 to 34 letters (inclusive) or better on ETDRS-like charts. Exclusion Criteria for Study Eye: - History of vitrectomy surgery, submacular surgery, other intraocular surgery, or any planned surgical intervention during the study period. - Cataract surgery without complications within three months preceding the screening visit or planned during the study period. - Aphakia or absence of the posterior capsule. Previous violation of the posterior capsule is also an exclusion criterion, unless it occurred as a result of yttrium-aluminum garnet laser posterior capsulotomy in association with prior, posterior chamber intraocular lens implantation. - Prior macular treatment with verteporfin, external beam radiation therapy, transpupillary thermotherapy, or any type of laser photocoagulation. - Prior treatment with IVT corticosteroids or implant (e.g., triamcinolone, ozurdex, iluvien). - Subretinal hemorrhage >50% of the total lesion area and/or involving the fovea. - Subfoveal fibrosis or subfoveal atrophy. - Retinal pigment epithelial tear involving the macula. - History of vitreous hemorrhage, rhegmatogenous retinal detachment, glaucoma-filtering surgery, tube shunts, or microinvasive glaucoma surgery, and corneal transplant. - History of rhegmatogenous retinal tears or peripheral retinal breaks within three months prior to the screening visit. - Actual or history of myopia >-8 diopters. - Uncontrolled ocular hypertension or glaucoma (defined as intraocular pressure (IOP) >25 millimeters of mercury (mm Hg) or a cup to disc ration >0.8, despite treatment with antiglaucoma medication) and any such condition the Investigator determines may require a glaucoma-filtering surgery during a participant's participation in the study. - Concurrent intraocular conditions (e.g., cataract, diabetic retinopathy, epiretinal membrane with traction, macular hole) that, in the opinion of the Investigator, could either: - Require medical or surgical intervention during the study period to prevent or treat visual loss that might result from that condition; or - Likely contribute to loss of BCVA over the study period if allowed to progress untreated; or - Preclude any visual improvement due to substantial structural damage. - Concurrent conjunctival, Tenon's capsule, and/or scleral condition in the supero-temporal quadrant of the eye (e.g., scarring, thinning, mass) that may affect the implantation, subsequent tissue coverage, and refill-exchange procedure of the PD implant. - Prior treatment with any medication for geographic atrophy. - Prior treatment with any anti-VEGF-C or anti-VEGF-D inhibitors. Exclusion Criteria for Fellow Eye - BCVA letter score using ETDRS charts of < 34 letters. - Treatment with anti-VEGF or anti-VEGF/Ang-2 agents within one month prior to Day 1 (for Part 1) or prior to the randomization visit (Part 3). Exclusion Criteria for Either Eye - CNV due to causes other than nAMD, such as ocular histoplasmosis, trauma, pathological myopia, angioid streaks, choroidal rupture, uveitis or central serous chorioretinopathy. - Prior participation in a clinical trial involving anti-VEGF drugs within six months prior to the screening visit, other than ranibizumab, aflibercept, or faricimab. - Active intraocular inflammation (grade trace or above), infectious conjunctivitis, keratitis, scleritis, or endophthalmitis. - History of uveitis, including history of any intraocular inflammation following intravitreal anti-VEGFor anti-VEGF/Ang-2 injections. - Prior treatment with brolucizumab. - Prior gene therapy for nAMD

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Zifibancimig
Part 1: multiple ascending doses by IVT injection. Each participant will receive zifibancimig at a constant volume of 50 microliter in the study eye. Part 2: participants will be randomized to one of two dose levels of zifibancimig in the PD implant. Part 3: Participants will receive one of the two dose levels of zifibancimig in the PD implant.
Ranibizumab
Participants will receive ranibizumab 100 mg/mL through the PD implant
Device:
Port Delivery Platform
Participants will receive intraocular refillable device that is surgically inserted into the eye for continuous delivery of drugs into the vitreous.

Locations

Country Name City State
United States Southeast Retina Center Augusta Georgia
United States Austin Clinical Research LLC Austin Texas
United States Austin Research Center for Retina Austin Texas
United States Retina & Vitreous of Texas Bellaire Texas
United States Envision Ocular, LLC Bloomfield New Jersey
United States Midwest Vision Research Foundation Chesterfield Missouri
United States Southwest Retina Consultants Durango Colorado
United States Cumberland Valley Retina Associates Hagerstown Maryland
United States Southeastern Retina Associates Knoxville Tennessee
United States Piedmont Eye Center Lynchburg Virginia
United States Barnet Dulaney Perkins Eye Center Mesa Arizona
United States Tennessee Retina PC. Nashville Tennessee
United States Mid Atlantic Retina - Wills Eye Hospital Philadelphia Pennsylvania
United States Associated Retina Consultants Phoenix Arizona
United States Sierra Eye Associates Reno Nevada
United States Retina Vitreous Assoc of FL Saint Petersburg Florida
United States Spokane Eye Clinical Research Spokane Washington
United States Southern Vitreoretinal Assoc Tallahassee Florida
United States Retina Associates of Florida, LLC Tampa Florida
United States Retina Consultants of Texas The Woodlands Texas

Sponsors (1)

Lead Sponsor Collaborator
Hoffmann-La Roche

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Percentage of Participants with Ocular and Systemic (Nonocular) Adverse Events (AEs) Part 1: Baseline up to Week 24; Part 2: Baseline up to Week 48; Part 3: Baseline up to Week 48
Primary Percentage of Participants with Ocular and Systemic (Nonocular) AEs during Post-operative and Follow-up Periods Part 2 and 3: From Day 1 to Week 4 and during follow up period (up to Week 48)
Primary Percentage of Participants with Adverse Events of Special Interest (AESIs) including Ocular AESIs Part 1: Baseline up to Week 24; Part 2: Baseline up to Week 48; Part 3: Baseline up to Week 48
Primary Percentage of Participants with AESIs including Ocular AESIs during the Postoperative and Follow-up periods Part 2 and 3: From Day 1 to Week 4 and during follow up period (up to Week 48)
Primary Duration of AESIs including Ocular AESIs Part 1: Baseline up to Week 24; Part 2: Baseline up to Week 48; Part 3: Baseline up to Week 48
Primary Duration of AESIs including Ocular AESIs during the Postoperative and Follow-up periods Part 2 and 3: From Day 1 to Week 4 and during follow up period (up to Week 48)
Primary Percentage of Participants with Adverse Device Effects (ADEs) Part 2: Baseline up to Week 48; Part 3: Baseline up to Week 48
Primary Duration of ADEs Part 2: Baseline up to Week 48; Part 3: Baseline up to Week 48
Primary Percentage of Participants with Anticipated Serious ADEs (ASADEs) Part 2: Baseline up to Week 48; Part 3: Baseline up to Week 48
Primary Duration of ASADEs Part 2: Baseline up to Week 48; Part 3: Baseline up to Week 48
Primary Change from Baseline in Early Treatment Diabetic Retinopathy Study - Best Corrected Visual Acuity (ETDRS-BCVA) Score ETDRS-BCVA will be used to quantify visual acuity. BCVA is measured using an eye chart and is reported as the number of letters read correctly using the ETDRS Scale (ranging from 0 to 100 letters) in the study eye. The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). An increase in the number of letters read correctly means that vision has improved. Part 3: Baseline (baseline visit, before implant insertion) to Week 48
Secondary Maximum Observed Concentration (Cmax) of Zifibancimig in Blood and Aqueous Humor (AH) Part 1: Baseline up to Week 24; Part 2: Baseline up to Week 144; Part 3: Baseline up to Week 144
Secondary Time of Maximum Concentration Observed (Tmax) of Zifibancimig in Blood and AH Part 1: Baseline up to Week 24; Part 2: Baseline up to Week 144; Part 3: Baseline up to Week 144
Secondary Concentration at the End of a Dosing Interval before the Next Dose Administration (Ctrough) of Zifibancimig in Blood and AH Part 1: Baseline up to Week 24; Part 2: Baseline up to Week 144; Part 3: Baseline up to Week 144
Secondary Area Under the Curve (AUC) of Zifibancimig in Blood and AH Part 1: Baseline up to Week 24; Part 2: Baseline up to Week 144; Part 3: Baseline up to Week 144
Secondary Percentage of Participants who did not meet Supplemental Treatment Criteria for the PD implant with Zifibancimig Part 3: Week 36, Week 40, and Week 44
Secondary Percentage of Participants who Gained or Lost =15, =10 =5 or =0 letters in ETDRS-BCVA score from Baseline ETDRS-BCVA will be used to quantify visual acuity. BCVA is measured using an eye chart and is reported as the number of letters read correctly using the ETDRS Scale (ranging from 0 to 100 letters) in the study eye. The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). An increase in the number of letters read correctly means that vision has improved. Part 3: Baseline to Week 48
Secondary Change from Baseline in Central Subfield Thickness (CST) Part 3: Baseline to Week 48
Secondary Change from Baseline Over Time in CST Part 3: Baseline to end of follow up period (up to Week 144)
See also
  Status Clinical Trial Phase
Recruiting NCT06262737 - Single-center Study Measuring OSDI Dry Eye Score in Patients Undergoing an Anti-VEGF Induction Protocol
Completed NCT02540954 - Efficacy and Safety of Two Different Aflibercept Regimens in Subjects With Neovascular Age-related Macular Degeneration (nAMD) Phase 3
Completed NCT00385333 - Metabolic Mapping to Measure Retinal Metabolism Phase 2
Completed NCT02510794 - Study of the Efficacy and Safety of the Ranibizumab Port Delivery System for Sustained Delivery of Ranibizumab in Patients With Subfoveal Neovascular Age-Related Macular Degeneration Phase 2
Completed NCT02390245 - Philadelphia Telemedicine Glaucoma Detection and Follow-Up Study N/A
Terminated NCT02228304 - Study of the Intravitreal Implantation of NT-503-3 Encapsulated Cell Technology (ECT) for the Treatment of Recurrent Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD) Phase 1/Phase 2
Completed NCT02181504 - A Study of Abicipar Pegol in Japanese Patients With Neovascular Age-related Macular Degeneration Phase 2
Recruiting NCT01521065 - An Open-label Study to Evaluate the Clinical and Economic Benefits of I-Ray in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration Phase 2
Completed NCT01204541 - A Single-Center Pilot Study to Assess Macular Function N/A
Completed NCT00769392 - Pilot Study: A Randomized Trial Of Anesthetic Agents For Intravitreal Injection N/A
Completed NCT00536016 - A Phase 1 Safety Study of Single and Repeated Doses of JSM6427 (Intravitreal Injection) to Treat AMD Phase 1
Withdrawn NCT00538538 - Subretinal Lucentis for Hemorrhagic Age-related Macular Degeneration (AMD) Phase 1
Completed NCT00533520 - Evaluation of Dosing Interval of Higher Doses of Ranibizumab Phase 4
Terminated NCT00403442 - Bevacizumab in Combination With Verteporfin Reduced and Standard Fluence in the Treatment of Hemorrhaged Lesions in Neovascular AMD Phase 1
Recruiting NCT00157976 - Double-Masked Study of Photrex (Rostaporfin) Photodynamic Therapy in the Treatment of Age-Related Macular Degeneration Phase 3
Completed NCT00242580 - A Safety and Efficacy Study Comparing the Combination Treatments of Verteporfin Therapy Plus One of Two Different Doses of Intravitreal Triamcinolone Acetonide and the Verteporfin Therapy Plus Intravitreal Pegaptanib Phase 3
Completed NCT00239928 - Clinical Study Of Pegaptanib Sodium (EYE001) For Wet-Type Age-Related Macular Degeneration Phase 2
Completed NCT00211458 - Treatment of Age-Related Macular Degeneration With Anecortave Acetate Phase 2
Completed NCT00095433 - Extension Study of rhuFab V2 in Subjects With Neovascular Age-Related Macular Degeneration (AMD) Phase 3
Completed NCT00006202 - Lutein for Age-Related Macular Degeneration Phase 2